§ Dr. Evan HarrisTo ask the Secretary of State for Health how much the NHS spent on respiratory syncytial virus (RSV) immunisations (synergis) in the last three years for which figures are available. [41476]
§ Yvette CooperThe information requested is not available. We have no central information on prescribing in hospitals, where this drug is primarily used.
§ Dr. Evan HarrisTo ask the Secretary of State for Health what guidance he provides to hospitals and health authorities on(a) whether to immunise at risk infants against RSV and (b) which infants would benefit from RSV immunisations. [41475]
§ Yvette CooperPalivizumab is a monoclonal antibody indicated for prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) requiring hospitalisation in children born at 35 weeks gestation or less and who are less than six months old at onset of the RSV season, or in children less than two years old who have received treatment for bronchopulmonary dysplasia within the last six months. It is given monthly during the RSV season. This information is published in the British National Formulary.